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Background: Everolimus was recently introduced as a second-line treatment for renal cell carcinoma (RCC) and
many other cancers. Several prospective studies have shown that serum creatinine levels are increased in a
significant proportion of patients receiving everolimus. However, data on the occurrence of acute kidney injury
(AKI) during everolimus treatment in clinical practice are sparse. Here, we report the incidence, risk factors,
and clinical significance of AKI associated with everolimus treatment in patients with cancer.
Methods: We analyzed patients who received everolimus for more than 4 weeks as an anticancer therapy. AKI was
defined as increase in creatinine levels from baseline levels greater than 1.5-fold.
Results: The majority of the 110 patients enrolled in this analysis had RCC (N=93, 84.5%). AKI developed in 21 (23%)
RCC patients; none of the patients (N=17) with other cancers had AKI. Fourteen of 21 cases were considered to be
everolimus-associated AKI, in which there were no other nephrotoxic insults other than everolimus at the onset of
AKI. The incidence of AKI increased progressively as baseline estimated glomerular filtration rate (eGFR) decreased
(10% in subjects with eGFR >90 mL/min/1.73 m2, 17% in subjects with eGFR 60–90 mL/min/1.73 m2, 28% in
subjects with eGFR 30–60 mL/min/1.73 m2, and 100% in subjects with eGFR 15–30 mL/min/1.73 m2; P=0.029
for trend). Baseline eGFR was an independent risk factor for the development of everolimus-associated AKI (hazard
ratio per 10 mL/min/1.73 m2 increase, 0.70; 95% confidential interval, 049–1.00; P=0.047). Nine of 14 patients with
everolimus-associated AKI continued receiving the drug at a reduced dose or after a short-term off period.
Administration of the drug was discontinued in four of 14 patients because of progression of an underlying
malignancy. Only one patient stopped taking the drug because of AKI.
Conclusions: This paper suggests that AKI is a common adverse effect of everolimus treatment, especially in
subjects with impaired renal function. However, the occurrence of AKI did not require the discontinuation of the
drug, and the treatment decision should be made via a multidisciplinary approach, including the assessment of the
oncological benefits of everolimus and other therapeutic options.
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Everolimus is a major active metabolite of sirolimus,
which acts as a selective inhibitor of the mammalian
target of rapamycin (mTOR) [1]. Everolimus has been
developed as an immunosuppressant that is adminis-
tered after solid organ transplantation based on its
antiproliferative properties [1,2]. In particular, an
mTOR-inhibitor-based regimen in which calcineurin
inhibitors are withdrawn or reduced has been evalu-
ated as a maintenance immunosuppressant therapy
to minimize calcineurin-inhibitor toxicity [2,3]. Although
mTOR inhibitors have been considered to lack nephrotox-
icity when used alone, the combination of mTOR inhibi-
tors and full-dose calcineurin inhibitors has been shown to
exacerbate nephrotoxicity. Moreover, the nephrotoxicity of
mTOR inhibitors has been demonstrated in patients with
glomerulonephritis and in experimental animal models of
glomerular injury [4,5]. Recently, everolimus received ap-
proval for use in the treatment of advanced renal cell car-
cinoma (RCC) and several other cancers at a dose of
10 mg once daily, which is a higher dose than that used
for immunosuppression [6-8]. Increased serum creatinine
level was one of the frequently reported laboratory abnor-
malities during observed in a phase 3 trial of everolimus for
metastatic renal cell cancer [6]. However, the information
regarding the nephrotoxicity associated with everolimus,
especially in cancer patients with clinical settings, is sparse.
Therefore, we conducted this research to evaluate the inci-
dence, severity, risk factors, and prognosis of acute kidney
injury (AKI) in patients receiving everolimus as an antican-
cer therapy. We were particularly interested in patients with
RCC who already had a decreased mass of functioning
nephrons because of nephrectomy, invasion of cancer, or
previous treatment with vascular endothelial growth factor
receptor/tyrosine kinase inhibitors (VEGFR-TKIs).
Methods
Patients
Between January 2009 and September 2013, 140 adult
patients (>18 years of age) who took everolimus as an
anticancer treatment at the Samsung Medical Center
were identified using electronic databases. We excluded
patients who received everolimus for less than 4 weeks
(N = 12), for whom there were insufficient data (N = 17),
or for whom the baseline estimated glomerular filtration
rate (eGFR) was less than 15 mL/min/1.73 m2 (N = 1).
Data from 110 patients were analyzed. At the Samsung
Medical Center, advanced RCC or hepatocellular carcin-
oma (HCC) that failed VEGFR-TKI treatment was an in-
dication for everolimus treatment. Generally, patients
received 10 mg of everolimus once daily; however, the
dose and schedule could be modified according to tox-
icity and tolerability. Most patients were followed every
4 weeks and laboratory tests including creatinine wereperformed at every visit. This research was approved by
the Institutional Review Board of the Samsung Medical
Center.
Data collection
Demographic data including age, sex, body mass index, the
malignancy that was targeted by everolimus, past medical
history of diabetes mellitus, hypertension, nephrectomy,
medication with angiotensin converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARBs) and di-
uretics, and prior treatment with VEGFR-TKIs were ex-
tracted from electronic medical records. Hypertension was
defined as a systolic blood pressure >140 mmHg, a diastolic
blood pressure >90 mmHg, or self-reported hypertension
with or without ongoing pharmacological treatment. Dia-
betes mellitus was defined as a history of type 1 or type 2
diabetes mellitus treated pharmacologically or controlled by
diet. Information regarding total dosage, treatment dur-
ation, and reason for discontinuation of everolimus, as well
as dose modification after AKI, was also collected. Labora-
tory data, including baseline serum creatinine level (defined
as the latest creatinine within 2 months before treatment),
eGFR, and urinalysis were extracted. eGFR was calculated
using the Chronic Kidney Disease Epidemiology Collabor-
ation (CKD-EPI) equation as follows: eGFR = 141 ×mini-
mum (creatinine/κ, 1)α ×maximum (creatinine/κ, 1)−1.209 ×
0.993age × 1.018 (if female), where κ is 0.7 for women and
0.9 for men and α is −0.329 for women and −0.411 for men
[9]. Serum creatinine levels were determined every 4 weeks
during treatment, and 1, 3, and 6 months after the discon-
tinuation of everolimus.
The primary outcome was the development of AKI,
which was defined according to the Acute Dialysis Qual-
ity Initiative (ADQI) criteria. Briefly, patients were classi-
fied in the “risk” category if serum creatinine increased
1.5-fold or eGFR decreased >25%, in the “injury” cat-
egory if serum creatinine increased 2-fold or eGFR
decreased >50%, and in the “failure” category if serum
creatinine increased 3-fold or eGFR decreased >75%
[10]. Time to AKI was defined as the interval between
the start of everolimus therapy and the onset of AKI.
AKI category was determined based on peak serum cre-
atinine. Recovery from AKI was defined as the return to
a serum creatinine within 1.2-fold of the baseline value.
Everolimus-associated AKI was defined as cases in which
there were no other nephrotoxic insults at the onset
of AKI, such as nephrotoxic drugs, contrast media,
hypotension, infection, urinary tract obstruction, or
volume depletion.
Statistical analysis
Data are expressed as the median with interquartile range
(IQR), or absolute number with percentages. Intergroup
differences were compared using the Mann–Whitney
Table 1 Baseline characteristics of the subjects according
to underlying malignancy
RCC (N = 93) Non-RCC (N = 17)
Male sex , no. (%) 77 (82%) 10 (63%)
Age (years) 59 (52, 67) 54 (48, 59)
BMI (kg/m2) 23.5 (20.0, 25.2) 23.8 (21.4, 25.3)
Diabetes mellitus (%) 17 (18%) 0 (0%)
Hypertension (%) 33 (36%) 2 (11%)
ACE inhibitor/ARB (%) 15 (16%) 1 (6%)
Diuretics (%) 40 (43%) 5 (29%)
Previous TKI Treatment (%) 93 (100%) 9 (53%)
Radical nephrectomy 74 (80%) 0 (0%)
Creatinine (mg/dL) 1.19 (1.01, 1.43) 0.78 (0.64, 0.86)
eGFR (mL/min/1.73 m2) 63 (51, 76) 104 (94, 132)
>90 10 (11%) 14 (82%)
60–90 41 (44%) 2 (12%)
30–60 40 (43%) 1 (6%)
15–30 2 (2%) 0 (0%)
Proteinuria (%) 25 (28.1%) 0 (0%)
Everolimus
Total dose (mg) 1155 (670, 1900) 790 (332, 1825)
Duration (weeks) 20 (12, 36) 12 (6, 26)
Data are presented as the median (IQR) or number (%).
RCC, renal cell carcinoma; BMI, body mass index; ACE inhibitor, angiotensin
converting enzyme inhibitor; ARB, angiotensin receptor blocker; TKI, tyrosine
kinase inhibitor; eGFR, estimated glomerular filtration rate.
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chi-squared analysis for categorical variables. The cumula-
tive incidence of AKI was determined using the Kaplan–
Meier method. Uni- and multivariate Cox proportional
models were fitted to identify risk factors of AKI. The
multivariate analysis included variables with a P-value <
0.1 according to the univariate analysis. We regarded
P-values < 0.05 as significant. All statistical analyses were
conducted using SPSS 21.0 (IBM Inc., Armonk, NY).
Results
Baseline characteristics of the subjects according to
underlying malignancy
A total of 110 patients met the inclusion criteria, and
the majority of patients (N = 93) received everolimus to
treat RCC. The remaining patients had HCC (N = 7),
pancreas neuroendocrine tumors (N = 5), lymphoma
(N = 2), or other tumors (melanoma, leiomyosarcoma,
and rectal carcinoid, N = 1 for each). Baseline charac-
teristics are shown for the two groups of patients
according to underlying malignancy, RCC vs non-RCC, as
these two groups showed quite different baseline charac-
teristics (Table 1). The median age was 59 years (range,
52–67 years) in the RCC group and 54 years (48–59 years)
in the non-RCC group. In the RCC group, the median
eGFR was 63 mL/min/1.73 m2 (51–76 mL/min/1.73 m2)
and 83 patients (89%) had decreased renal function (de-
fined as GFR values <90 mL/min/1.73 m2), whereas most
individuals in the non-RCC group had normal renal func-
tion. In the RCC group, all patients received VEGFR-TKI
therapy, and 74 (80%) patients received radical nephrec-
tomy before treatment with everolimus. Twenty-five (28%)
patients in the RCC group had proteinuria at the baseline.
The total dosage and duration of everolimus treatment
were 1155 mg (670–1900 mg) and 20 weeks (12–36
weeks), respectively, in the RCC group.
Cumulative incidence of AKI
AKI developed in 21 (23%) patients in the RCC group
during everolimus treatment, whereas none of the pa-
tients in the non-RCC group experienced AKI. After ex-
clusion of the patients with other nephrotoxic insults at
the onset of AKI, everolimus-associated AKI developed
in 14 (16.2%) patients. Figure 1A presents the cumula-
tive incidence of AKI in the RCC group. Most cases of
AKI (N = 19, 90%) occurred within 16 weeks of everoli-
mus treatment, and all everolimus-associated AKI cases
occurred within 16 weeks of treatment, with a median
interval of 8 weeks (4–12 weeks) (Figure 1B).
Association between AKI risk and baseline eGFR in the
RCC group
The incidence of all-cause AKI increased progressively
as the baseline eGFR decreased. Figure 2 shows that theincidence of AKI was 10% in patients with a baseline
eGFR >90 mL/min/1.73 m2, 17% in those with a baseline
eGFR of 60–90 mL/min/1.73 m2, 28% in those with a
baseline eGFR of 30–60 mL/min/1.73 m2, and 100% in
those with a baseline eGFR of 15–30 mL/min/1.73 m2
(P = 0.029 for trend). The incidence of everolimus-
associated AKI also increased progressively with decreas-
ing eGFR (P = 0.004 for trend). All patients with a baseline
eGFR <30 mL/min/1.73 m2 experienced AKI.
To identify the risk factors of AKI in patients with
RCC, we used Cox proportional hazard models (Table 2).
On univariate analyses, older age and lower baseline
eGFR were associated with a higher risk of everolimus-
associated AKI. Multivariate analysis revealed that base-
line eGFR was the only risk factor for AKI, and that an
eGFR increase of 10 mL/min/1.73 m2 was associated
with a 0.7-fold lower risk of AKI (95% confidence inter-
val, 0.49–1.00; P = 0.047). The presence of proteinuria at
the baseline was not independently associated with a
higher risk of AKI.
Outcome and clinical significance of everolimus-associated
AKI in the RCC group
Next, we examined the outcome of everolimus-associated
AKI (N = 14) according to the ADQI criteria. Ten patients
Figure 1 Cumulative incidence of all-cause AKI (A) and everolimus-associated AKI (B) in the RCC group.
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mus treatment without renal deterioration. In half of these
patients, the dosage was reduced to 5 mg per day, and two
patients held off the medication for 1 week and 1 month,
respectively, and resumed treatment without dose modifi-
cation. The remaining three patients discontinued the
drug because of progression of the underlying cancer. In
three patients in the AKI-injury category, kidney function
was recovered after the discontinuation or the reduction
of the dosage of the drug; one of these three patients with-
held medication for 2 weeks, and resumed the therapy at
50% of the previous everolimus dose, whereas another pa-
tient took everolimus with a 50% dose reduction without
discontinuation of the medication. The remaining patient
in the AKI-injury category discontinued everolimus be-
cause of the development of pneumonia, and not of AKI,
and kidney function recovered to the baseline level. One
patient in the AKI-failure category discontinued everoli-
mus treatment eventually, and kidney function recovered
thereafter.Figure 2 Incidence of AKI according to baseline eGFR categories in the
increased progressively with decreasing eGFR (P = 0.029 and P = 0.004 for trenTo assess the effects of AKI on treatment decision in
RCC patients, we compared treatment duration and rea-
son for drug discontinuation between the AKI and non-
AKI groups (Table 3). Treatment duration was 18 weeks
(9–35 weeks) and 20 weeks (12–36 weeks) in the AKI
and non-AKI groups, respectively, and the total dose of
everolimus was 1050 mg (615–1913 mg) and 1172 mg
(683–1915 mg) in the AKI and non-AKI groups, respect-
ively (not significant; NS). The most common reason for
drug discontinuation in both groups was progression of an
underlying malignancy (67% in the AKI group and 68% in
the non-AKI group; NS).
Discussion
This retrospective analysis examined the incidence, risk
factors, and clinical implications of the development of
AKI during everolimus treatment in real-world cancer
patients. Twenty-three percent of patients who received
everolimus to treat RCC experienced AKI, and 67% of
AKI events were considered everolimus-associated AKIRCC group. The incidence of all-cause AKI and everolimus-associated AKI
d, respectively).
Table 2 Risk factors of everolimus-associated AKI in the RCC group: Cox proportional hazard models
Variable Univariate analysis Multivariate analysis*
HR (95% CI) P-value HR (95% CI) P-value
Age (per 10 years) 1.83 (1.05–3.21) 0.034 1.54 (0.84–2.81) 0.162
Male (vs female) 0.85 (0.19–3.82) 0.836
DM 0.70 (0.16–3.14) 0.643
HTN 0.74 (0.23–2.36) 0.609
eGFR (per 10 mL/min/1.73 m2) 0.74 (0.57–0.96) 0.022 0.70 (0.49–1.00) 0.047
Radical nephrectomy 0.64 (0.20–2.06) 0.456
Proteinuria 2.23 (0.75–6.63) 0.150
ACE inhibitor/ARB 1.21 (0.34–4.34) 0.769
Diuretics 1.09 (0.38–3.13) 0.880
AKI, acute kidney injury; RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ACE inhibitor, angiotensin
converting enzyme inhibitor; ARB, angiotensin receptor blocker.
*This model includes age, sex, and eGFR.
Ha et al. BMC Cancer 2014, 14:906 Page 5 of 7
http://www.biomedcentral.com/1471-2407/14/906without other nephrotoxic insults. In contrast to RCC
patients, AKI events were not observed in any of the pa-
tients with other cancers, for whom baseline eGFR was
much higher than the levels detected in patients with
RCC. Baseline eGFR was the only independent risk fac-
tor of everolimus-associated AKI among patients with
RCC. Differences in treatment duration and in the rea-
son for drug discontinuation were not observed between
the AKI group and non-AKI groups, which indicates
that the occurrence of AKI did not have a high impact
on therapeutic decision making by clinicians.
As many new chemotherapeutic agents have emerged
in recent decades, nephrologists should be alerted to the
potential nephrotoxicity of new drugs [11-14]. VEGFR-
TKI is a representative target agent with well-established
nephrotoxicity [11,15]. Everolimus is familiar to nephrolo-
gists as an alternative immunosuppressant to calcineurin
inhibitors after kidney transplantation, with the advantage
of lack of nephrotoxicity [1-3]. However, everolimus has
been examined as a treatment for various cancers and
renal adverse effects have been reported [6,16]. In fact, the
incidence and severity were divergent in clinical studies
and target cancers, which confused clinicians regarding
the recognition of drug nephrotoxicity [17-19]. ThisTable 3 Treatment duration and reason for final cessation
of everolimus treatment in the RCC group
AKI group Non-AKI group P-value
Treatment duration (weeks) 18 (9, 35) 20 (12, 36) NS
Total dose (mg) 1050 (615, 1913) 1173 (683, 1915) NS
Discontinuation of drug 15 (71%) 53 (74%) NS
Reason for discontinuation NS
Disease progression 10 (67%) 35 (66%)
Adverse effect 2 (13%) 9 (17%)
Self-withdrawal 3 (20%) 9 (17%)
RCC, renal cell carcinoma; AKI, acute kidney injury; NS, not significant.research clearly showed that AKI was not uncommon in
subjects with impaired kidney function, but was rare in
subjects with normal kidney function. Impaired kidney
function at the baseline is a general feature in subjects
with RCC who have started to take everolimus. Therefore,
clinicians should be cautious about potential nephrotox-
icity when prescribing everolimus to RCC patients.
It is not surprising that most RCC patients have de-
creased kidney function when they initiate everolimus
treatment. Currently, everolimus is indicated in meta-
static RCC after progression on VEGFR-TKI therapy
[20,21]. Thus, patients have a high probability of reduced
functioning in nephrons because of previous radical neph-
rectomy, the presence of a neoplastic mass replacing renal
parenchyma, or previous exposure to VEGFR-TKI therapy.
We assumed that nephrons with reduced function render
RCC patients vulnerable to the adverse renal effects of
everolimus. Several studies have demonstrated that mTOR
inhibitors have nephrotoxicity in injured kidneys [5,22].
The combination of mTOR inhibitors with full-dose
calcineurin inhibitors exacerbates the nephrotoxicity of
the drug [1]. In addition, everolimus treatment converts
the reversible glomerulonephritis into chronic progressive
disease in Thy1 models via the inhibition of glomerular re-
pair [5]. Moreover, everolimus treatment induces renal de-
terioration and proteinuria in the remnant kidney model
[22]. Consistently, baseline eGFR was an independent risk
factor of everolimus-associated AKI in this analysis.
The observation that the nephrotoxicity of everolimus
was evident in patients with RCC compared with kidney
transplant recipients who also had reduced nephron func-
tioning was not an unexpected finding. The dosage of
everolimus as an anticancer treatment is 10 mg per day,
which is about three times higher than that used for im-
munosuppression in transplantation patients [1,2,6,7]. An
experimental study showed that everolimus-induced glom-
erular injury developed in a dose-dependent manner [5].
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ued or resumed in most patients with AKI without renal
deterioration, unless there was progressive disease or
other significant adverse events. Most of the AKI events
(13 of 14) were mild and nonprogressive (categorized
into AKI-risk or AKI-injury according to ADQI criteria)
during everolimus treatment for 20 weeks. This finding
has important clinical significance when considering that
the drug is indicated for patients with few therapeutic
options. In addition, decreased renal function was recov-
ered after the cessation of treatment, including one pa-
tient who was in the AKI-failure category.
There were some limitations to this research. First, as
a retrospective analysis, selection and misclassification
biases were inevitable. However, everolimus treatment in
cancer patients is standardized at our center, and serum
creatinine is monitored regularly, which might minimize
those biases. Second, the effects of everolimus-associated
AKI on patient mortality were not elucidated in this re-
search. Third, we did not evaluate the incidence of pro-
teinuria and increment of preexisting proteinuria, which
are other renal adverse effects of anti-angiogenic drugs. In
addition, this research did not provide any information on
the histological features of everolimus-associated AKI, be-
cause none of subjects who experienced AKI underwent
kidney biopsy, probably because the AKI was mostly mild
and reversible.Conclusions
In conclusion, we demonstrated that AKI associated
with everolimus, which is used as an anticancer therapy,
is not uncommon in subjects with impaired kidney func-
tion, whereas it is rare in subjects with normal kidney
function. Therefore, clinicians should be cautious about
potential nephrotoxicity when prescribing everolimus to
patients with decreased kidney function, in whom serial
measurements of serum creatinine are needed. In addition,
everolimus treatment could be continued at a reduced dose
or after a short-term off period even in patients with AKI
without renal deterioration. Therefore, the treatment deci-
sion should be made using a multidisciplinary approach
that includes the assessment of the oncological benefit of
everolimus and other therapeutic options for cancer in each
individual. A large-scale, prospective study is needed to
clarify the incidence of everolimus-associated AKI and its
impact on patients’ survival.
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